Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $1.49, may note compare to the analyst estimate of $1.76. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $63.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.